| Nov 14 |
ALX Oncology names Alan Sandler as chief medical officer
|
| Nov 14 |
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
|
| Nov 8 |
ALX Oncology GAAP EPS of -$0.58
|
| Nov 7 |
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
|
| Nov 4 |
ALX Oncology Announces November Investor Conference Participation
|
| Nov 1 |
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
|
| Oct 10 |
Millennium Management LLC Reduces Stake in ALX Oncology Holdings Inc
|
| Sep 12 |
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
|
| Sep 9 |
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
|
| Sep 4 |
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
|
